【摘要】 目的　探讨氯沙坦对充血性心力衰竭 (CHF)患者左室质量指数的影响及其临床疗效。方法　CHF患者 5 1例(NYHA心功能分级为Ⅱ～Ⅳ级 ) ,按照随机化区组原则分为A组 (氯沙坦组 )和B组 (依那普利组 ) ,观察用药前及用药后12周心功能 (NYHA分级 )、心胸比变化。心脏超声心动图仪测定用药前及用药后 12周左室舒张末期内径及左室质量指数改变。结果　 5 1例充血性心力衰竭患者心胸比、左室舒张末期内径及左室质量指数超过正常范围。氯沙坦组治疗后心功能改善Ⅰ～Ⅱ级占 87% ,恶化 13%。两组治疗 12周心胸比、左心室舒张末期内径及左室质量指数较治疗前降低 (P <0 0 5 )。结论　氯沙坦治疗CHF患者可获得有益的临床效应 ,延迟或逆转左心室肥厚 ,并具有较好的耐受性和安全性。更多还原

【Abstract】 Objective To study the effects of losartan on clinical effects and left ventricular mass index(LVMI) in patients with congestive heart failure (CHF) through comparing losartan with enalapril in CHF. Methods 51 patients with New York Heart Association(NYHA) class Ⅱ～Ⅳ CHF were randomised to 12 weeks of active therapy, either to losartan ( n =25 ) or to enalapril ( n =26). Left ventricular internal dimension at end diastole(LVIDd) and LVMI were assessed at baseline and after 12 weeks of therapy by echocardiograms. Results Cardiothoracic ratio,LVIDd and LVMI increase was present in patients with CHF. NYHA function class improved 87% of losartan treated patients and 83% of enalapril treated patients were Ⅰ orⅡafter 12 weeks compared with cardiac function at baseline.Cardiothoracic ratio,LVIDd and LVMI at 12 weeks of therapy decreased from pretreatment baseline in two groups( P <0 05). Conclusion Oral losartan for patients with CHF can result in beneficial clinical effects,defering and reversing left ventricular hypertrophy(LVH) and it has the greatest tolerability and safty.更多还原